最新ニュース Redwire (NYSE:RDW) 株価情報

REDWIRE CORP

Redwire

Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.

Redwire Corp

REDWIRE CORP          -CW27

REDWOOD GROUP INTL INC by Redwood Group International

Redwood Group International

Radware Ltd

REDROW PLC by REDROW PLC

WIIM

VUZI

VUZI stock has given up its prior gain. Vuzix shares were trading higher after the company, along with Himax Technologies, announced its AR optical module will jointly debut at Display Week 2025.

Oppenheimer analyst Jeff Jones maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Outperform and lowers the price target from $21 to $20.

News

Price Target

Analyst Ratings

YMAB

Oppenheimer Maintains Outperform on Y-mAbs Therapeutics, Lowers Price Target to $20

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: S&P Roughly Flat At Open, AMD Rises On Buyback

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) with a Overweight and lowers the price target from $20 to $16.

Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $16

Global

Charles Gasparino Posts On X "Scoop: Trade-tariff deals with Japan and South Korea said to be "close," according to me Wall Street sources close to the White House. Timing unclear. India deal as well though it has been throttled by the tensions with Pakistan..."

INVZ

INVZ stock has given up its prior gain. Innoviz Technologies shares were trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance with its midpoint above estimates.

Wells Fargo analyst Yanan Zhu maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Overweight and lowers the price target from $50 to $45.

ARCT

Wells Fargo Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $45

Oppenheimer analyst Michael Wiederhorn maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Outperform and lowers the price target from $600 to $400.

Oppenheimer Maintains Outperform on UnitedHealth Group, Lowers Price Target to $400

ALLO

Allogene Therapeutics shares are trading lower after the company reported Q1 financial results. Also, Baird and Oppenheimer lowered their respective price targets on the stock.

Cruise line stocks are historically among the strongest seasonal performers in the S&amp;P 500 heading into the second half of May, with Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) averaging double-digit returns over a <a href="https://www.benzinga.com/topic/seasonality">three-week window.</a>
Historical data from Seasonax platforms shows that from May 14 to early June, these three stocks have consistently outperformed over the past decade, with average gains north of 10%. 
Among all S&amp;P 500 constituents, they rank at the very top for late-spring seasonality. Seasonal strength is typically fueled by ramping summer demand, strong forward bookings, and an uptick in consumer travel spending ahead of peak vacation months.
Here are the top five S&amp;P 500 stocks by average return in a three-week period starting from May 14:
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Stock</th>
<th>Avg. Return (Last 10 years)</th>
<th>Max Profit</th>
<th>Max Loss</th>
<th>Win Rate</th>
<th>Pattern Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norwegian Cruise Line</td>
<td>+13.75%</td>
<td>+149.63%</td>
<td>-6.59%</td>
<td>5/10</td>
<td>May 14 – Jun 7</td>
</tr>
<tr>
<td>Caesars Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>)</td>
<td>+11.98%</td>
<td>+102.49%</td>
<td>-0.11%</td>
<td>9/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Royal Caribbean</td>
<td>+11.52%</td>
<td>+113.71%</td>
<td>-7.48%</td>
<td>6/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Carnival Corp.</td>
<td>+11.28%</td>
<td>+103.02%</td>
<td>-5.19%</td>
<td>5/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</td>
<td>+10.69%</td>
<td>+88.13%</td>
<td>-4.95%</td>
<td>8/10</td>
<td>May 14 – Jun 7</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Seasonax</figcaption></figure>
<h3 class="wp-block-heading">RCL Sees Strong Summer Bookings</h3>
In a note from late April, Goldman Sachs analyst Lizzie Dove pointed to a strong reversal in booking momentum despite broader macro uncertainty and uneven travel data across the sector.
April bookings at RCL exceeded the same month last year, while close-in bookings remained firm. 
The company also reported stronger-than-usual onboard spending and pre-cruise purchases. Forward bookings for 2026 were tracking in line with 2024 levels but at higher prices—a sign of pricing power in an inflation-sensitive market.
With approximately 86% of the 2025 cruise calendar already booked, Dove's team raised their estimates and lifted the stock's price target from $245 to $260. However, they retained a slightly more cautious tone in 2026, pending more clarity on consumer resilience.
Since hitting tariff-driven lows on April 9, shares of RCL have surged 50% through mid-May —more than twice the gain of the S&amp;P 500. CCL shares matched the performance during the same period. 
<h3 class="wp-block-heading">NCLH Flags Demand Softness Amid Macro Pressures</h3>
In contrast, Norwegian Cruise Line is facing a different set of conditions. 
In early May, Bank of America analyst Andrew Didora highlighted NCLH as the first in the group to show softness in its 12-month forward-booked position.
While this wasn't viewed as unexpected—given the macro backdrop, consumer sentiment, and fare discounts introduced under the Oceania brand—it raised questions about forward pricing discipline across the cruise industry. Didora added that weakening demand isn't isolated to NCLH, and other operators may be seeing similar dynamics. 
BofA cut its 2025 and 2026 EPS forecasts for NCLH by 3% and 2%, now expecting $2.07 and $2.53, respectively. It revised the price objective down from $23 to $20 while maintaining a Neutral rating on concerns around leverage and top-line pressures.
Shares of NCLH have rallied 36% since April lows, underperforming versus peers. 
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45298562/chipmakers-enter-bullish-seasonal-window-5-stocks-that-could-outperform">Chipmakers Enter Bullish Seasonal Window: 5 Stocks That Could Outperform </a></li>
</ul>
Photo: Shutterstock

Travel

ENPH

NCLH

Cruises Set Sail Ahead Of Summer Boom: These 3 S&P 500 Stocks Show Strongest Late-May Seasonality

Oppenheimer analyst Jay Olson maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Outperform and lowers the price target from $15 to $13.

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $13

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Equal-Weight and lowers the price target from $1.5 to $1.

ADAP

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1

Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Overweight and lowers the price target from $16 to $13.

ITOS

Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $13

CREX

Creative Realities shares are trading higher. The company reported Q1 financial results.

Oppenheimer analyst Timothy Horan initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Outperform rating and announces Price Target of $15.

Initiation

Core Scientific, Inc. - Class A Common Stock

CORZ

Oppenheimer Initiates Coverage On Core Scientific with Outperform Rating, Announces Price Target of $15

Wells Fargo analyst Larry Biegelsen maintains Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) with a Equal-Weight and lowers the price target from $1.29 to $0.68.

HYPR

Wells Fargo Maintains Equal-Weight on Hyperfine, Lowers Price Target to $0.68

The Tampa Bay Lightning have entered into a multi-year media rights agreement with Scripps Sports, which will make it easier than ever for fans throughout the Tampa Bay area to watch Lightning hockey games for free beginning with the start of the 2025-26 NHL season this fall.
This new agreement allows The E.W. Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) to produce and distribute all preseason, regular season and first-round playoff Lightning games that are not allocated exclusively to national broadcasts.
 &nbsp;

Tampa Bay Lightning Enters Into Multi-year Media Rights Agreement With Scripps Sports

BDSX

Biodesix shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 sales guidance below estimates.

By Javier Hasse via <a href="https://elplanteo.com/industria-cannabis-uruguay-2025/">El Planteo</a>
As debates over <a href="https://www.benzinga.com/cannabis">cannabis</a> reform continue across the globe, one country has a full decade of experience to draw from—and it just lost the man who helped make it happen.
This week, <a href="https://elplanteo.com/pepe-mujica-diario-che-guevara/">José "Pepe" Mujica</a>, the former Uruguayan president who oversaw the world's first full legalization of adult-use cannabis, <a href="https://www.benzinga.com/markets/cannabis/25/05/45392507/first-president-to-legalize-cannabis-has-died-honoring-uruguays-pepe-mujicas-legacy">passed away at the age of 89</a>. Widely revered for his humility, progressive ideals and radical honesty, Mujica's cannabis law was never about business; it was about dismantling hypocrisy and improving public health.
A decade later, the legacy of that 2013 law was front and center at C-Days 2025, a global cannabis and psychedelics summit held in Barcelona. Speaking at the event, <a href="https://elplanteo.com/industria-cannabis-uruguay-2025/">Mercedes Ponce de León</a>, founder of Latinnabis and director of Expo Cannabis Uruguay, offered a data-rich overview of Uruguay's cannabis model: its results, its limits and what it can teach the rest of the world.
<h3 class="wp-block-heading">Three Legal Channels, Over 100,000 Registered Consumers</h3>
Uruguay's adult-use system offers three legal pathways for non-medical cannabis access:
<ul class="wp-block-list">
<li>Home grow: Up to 6 flowering female plants and 480 grams per year.</li>
<li>Cannabis clubs: Non-profit associations of 15 to 45 members, with up to 99 plants and a 40-gram monthly cap per person.</li>
<li>Pharmacies: Up to 10 grams per week, sold in 5-gram packs, with four THC-limited strains authorized (up to 20% THC).</li>
</ul>
As of early 2025, 102,125 users were officially registered across these access points:
<ul class="wp-block-list">
<li>11,465 home growers</li>
<li>15,162 cannabis club members</li>
<li>75,498 pharmacy purchasers</li>
</ul>
There are also more than 460 licensed clubs and 40 pharmacies participating in the program.
<h3 class="wp-block-heading">What's Available In Pharmacies—And At What Cost?</h3>
Uruguay's state-controlled pharmacy model currently offers four cannabis strains, each with a unique THC/CBD profile and pricing structure:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Strain</th>
<th>%THC</th>
<th>%CBD</th>
<th>Psychoactivity</th>
<th>Price (UYU)</th>
<th>Approx. USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfa</td>
<td>≤9</td>
<td>≥3</td>
<td>Medium/Low</td>
<td>$470</td>
<td>$11.24</td>
</tr>
<tr>
<td>Beta</td>
<td>≤9</td>
<td>≥3</td>
<td>Medium/Low</td>
<td>$490</td>
<td>$11.71</td>
</tr>
<tr>
<td>Gamma</td>
<td>≤15</td>
<td>≤1</td>
<td>High</td>
<td>$550</td>
<td>$13.15</td>
</tr>
<tr>
<td>Épsilon</td>
<td>≤20</td>
<td>≤1</td>
<td>High</td>
<td>$600</td>
<td>$14.34</td>
</tr>
</tbody>
</table>
</figure>
While pharmacies remain the most used access point, Mercedes Ponce de León noted that restrictions on potency, format and availability continue to limit impact and consumer satisfaction.
<h3 class="wp-block-heading">Is It Working?</h3>
Yes, though not without caveats. According to official data shared during her presentation:
<ul class="wp-block-list">
<li>Problematic cannabis use has remained stable at 2.1% since 2011.</li>
<li>Overall cannabis consumption declined from 14.6% in 2018 to 12.3% in 2024.</li>
<li>Average age of first use rose from 18 to 20 years.</li>
<li>The illicit market has shrunk significantly.</li>
</ul>
Meanwhile, Uruguay's 2024 National Drug Survey showed that 37% of cannabis users now access the plant through legal means.
<h3 class="wp-block-heading">What Still Needs Work?</h3>
Despite strong public health outcomes, the model faces several persistent challenges:
<ul class="wp-block-list">
<li>Lack of product variety and innovation</li>
<li>Uneven geographic access, with few pharmacies outside major cities</li>
<li>Logistical and financial barriers to exports</li>
<li>A broader drug policy framework that remains punitive in other areas</li>
</ul>
Ponce de León outlined four priority actions for 2025 and beyond:
<ol class="wp-block-list">
<li>Foster stronger public-private collaboration</li>
<li>Invest in research and development</li>
<li>Update regulations to expand legal access and improve user experience</li>
<li>Integrate Uruguay into global markets through ethical and sustainable trade</li>
</ol>
<h3 class="wp-block-heading">What&#8217;s Next?</h3>
Uruguay did what many countries are still debating: build a legal cannabis system that reduces harm, shrinks the illicit market and respects consumer rights. The outcomes are measurable. But so are the gaps.
In Ponce de León's words, "The positive impact is proven. But if the framework isn't updated—if access doesn't expand and innovation isn't guaranteed—the model risks becoming symbolic rather than functional."
As the world mourns the passing of Pepe Mujica, Uruguay's cannabis experiment stands as part of his lasting legacy. The road ahead will determine whether that legacy deepens—or stalls.
This article is from an external, unpaid contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
Photo: Shutterstock

Cannabis

Latin America

Legal Cannabis, 10 Years Later: Real Data From The First Country To Do It

Oppenheimer analyst Timothy Horan initiates coverage on Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) with a Outperform rating and announces Price Target of $200.

Oppenheimer Initiates Coverage On Digital Realty Trust with Outperform Rating, Announces Price Target of $200

Press Releases

Redwire and ispace-U.S. Sign MOU to Jointly Pursue Commercial Lunar Exploration Missions

Small Cap

STOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of PLYA, BRKL, RDFN, RDW to Act Now

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BRKL, RDW on Behalf of Shareholders

Redwire Awarded Contract From Thales Alenia Space to Provide Docking System for European Habitation Module on the Gateway Lunar Space Station

Redwire Expands In-Space Drug Development Program, Launches New PIL-BOX Technology and Cancer-Detection Experiment

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICAD, WBA, RDW on Behalf of Shareholders

Redwire Corporation to Report First Quarter 2025 Results on May 12, 2025

Redwire Chief Scientist Dr. Kenneth Savin Named to TIME's 2025 TIME100 Health List of the 100 Most Influential People in Global Health

Redwire Corporation Reports First Quarter 2025 Financial Results

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TASK, PHX, HOFV, RDW on Behalf of Shareholders

Comments

Redwire

ニュース

最新ニュース Redwire (NYSE:RDW) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル